Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir.
Wohl DA, Bhatti L, Small CB, Edelstein H, Zhao HH, Margolis DA, DeJesus E, Weinberg WG, Ross LL, Shaefer MS. Wohl DA, et al. Among authors: shaefer ms. HIV Med. 2016 Feb;17(2):106-17. doi: 10.1111/hiv.12281. Epub 2015 Jul 14. HIV Med. 2016. PMID: 26176344 Free PMC article. Clinical Trial.
Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial.
Wohl DA, Bhatti L, Small CB, Edelstein H, Zhao HH, Margolis DA, DeJesus E, Weinberg WG, Ross LL, Shaefer MS. Wohl DA, et al. Among authors: shaefer ms. PLoS One. 2014 May 13;9(5):e96187. doi: 10.1371/journal.pone.0096187. eCollection 2014. PLoS One. 2014. PMID: 24825167 Free PMC article. Clinical Trial.
Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir.
Robertson K, Maruff P, Ross LL, Wohl D, Small CB, Edelstein H, Shaefer MS. Robertson K, et al. Among authors: shaefer ms. J Neurovirol. 2019 Feb;25(1):22-31. doi: 10.1007/s13365-018-0680-y. Epub 2018 Oct 8. J Neurovirol. 2019. PMID: 30298202 Free PMC article. Clinical Trial.
Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
Squires KE, Young B, Dejesus E, Bellos N, Murphy D, Zhao HH, Patel LG, Ross LL, Wannamaker PG, Shaefer MS; ARIES study team. Squires KE, et al. Among authors: shaefer ms. AIDS. 2010 Aug 24;24(13):2019-27. doi: 10.1097/QAD.0b013e32833bee1b. AIDS. 2010. PMID: 20613461 Clinical Trial.
Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.
Young B, Squires KE, Ross LL, Santiago L, Sloan LM, Zhao HH, Wine BC, Pakes GE, Margolis DA, Shaefer MS; Aries EPZ108859 Study Team. Young B, et al. Among authors: shaefer ms. AIDS Res Hum Retroviruses. 2013 Feb;29(2):350-8. doi: 10.1089/aid.2012.0278. Epub 2012 Dec 5. AIDS Res Hum Retroviruses. 2013. PMID: 23039030 Free PMC article. Clinical Trial.
Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine.
Young B, Squires KE, Tashima K, Henry K, Schneider S, LaMarca A, Zhao HH, Ross LL, Shaefer MS. Young B, et al. Among authors: shaefer ms. HIV Clin Trials. 2015 Aug;16(4):125-9. doi: 10.1179/1528433614Z.0000000017. Epub 2015 Jul 2. HIV Clin Trials. 2015. PMID: 26133089 No abstract available.
79 results